Burning Rock Biotech Limited American Depositary Shares (BNR) Stock Price

BNRStock

$12.90+59.46%52W

Market Cap$136.05M

P/E—

PEG Ratio—

Div yield—

Beta1.56

BNR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-37.96%

Price vs S&P 500 (4W)-11.10%

VGM Score42.30

Book Value / Share (Quarterly)$0.71

P/TBV (Annual)2.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.42%

Cash Flow / Share (Quarterly)$-0.02

Price vs S&P 500 (YTD)-47.70%

Gross Margin (TTM)74.55%

Net Profit Margin (TTM)-13.59%

EPS (TTM)$-0.10

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-0.10

Revenue Growth (5Y)4.65%

EPS (Annual)$-0.08

ROI (Annual)-10.30%

Gross Margin (Annual)74.67%

Net Profit Margin (5Y Avg)-105.68%

Cash / Share (Quarterly)$0.59

Revenue Growth QoQ (YoY)-9.28%

ROA (Last FY)-6.75%

Revenue Growth TTM (YoY)-6.65%

EBITD / Share (TTM)$-0.09

ROE (5Y Avg)-56.42%

Operating Margin (TTM)-12.99%

Cash Flow / Share (Annual)$-0.05

P/B Ratio2.21x

P/B Ratio (Quarterly)1.19x

Net Income / Employee (Annual)$-12,401

EV / Revenue (TTM)1.36x

Net Interest Coverage (TTM)-10.37x

ROA (TTM)-8.58%

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)2.99x

Quick Ratio (Quarterly)2.77x

3-Month Avg Trading Volume0.03M

52-Week Price Return59.46%

Revenue / Employee (TTM)$112,151

Tangible BV / Share (Quarterly)$0.71

P/S Ratio (Annual)2.03x

Asset Turnover (Annual)0.66x

52-Week High$6.23

Operating Margin (5Y Avg)-107.01%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)-41.94%

Tangible BV CAGR (5Y)-26.04%

26-Week Price Return-28.05%

Quick Ratio (Annual)2.68x

13-Week Price Return34.30%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.05x

Enterprise Value$101.92M

Revenue / Share Growth (5Y)-39.50%

Asset Turnover (TTM)0.63x

Book Value / Share Growth (5Y)-26.11%

Revenue / Employee (Annual)$120,862

Inventory Turnover (Annual)2.29x

Pretax Margin (Annual)-9.97%

Cash / Share (Annual)$0.68

3-Month Return Std Dev111.79%

Gross Margin (5Y Avg)70.34%

Net Income / Employee (TTM)$-15,240

ROE (Last FY)-10.34%

Net Interest Coverage (Annual)-9.73x

EPS Basic Excl Extra (Annual)$-0.08

P/FCF (TTM)27.82x

Receivables Turnover (TTM)2.59x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.10

Receivables Turnover (Annual)3.10x

ROI (TTM)-12.92%

P/S Ratio (TTM)2.19x

Pretax Margin (5Y Avg)-105.20%

Revenue / Share (Annual)$0.76

Tangible BV / Share (Annual)$0.76

Price vs S&P 500 (52W)43.92%

Year-to-Date Return-35.98%

5-Day Price Return-14.00%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-40.98%

Net Profit Margin (Annual)-10.26%

Month-to-Date Return-26.83%

EBITD / Share (Annual)$-0.05

Operating Margin (Annual)-10.16%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-56.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.10

P/TBV (Quarterly)1.19x

P/B Ratio (Annual)2.77x

Inventory Turnover (TTM)2.61x

Pretax Margin (TTM)-13.27%

Book Value / Share (Annual)$0.76

Price vs S&P 500 (13W)31.62%

Beta1.56x

Revenue / Share (TTM)$0.69

ROE (TTM)-12.97%

52-Week Low$1.01

vGradeC

gGradeF

mGradeB

vgmGradeC

BNR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2023	May 30, 2023	-$2.08	-$2.70	-30.22%(-$0.63)
Q4 2022	Mar 28, 2023	-$2.84	-$3.15	-11.05%(-$0.31)
Q3 2022	Nov 16, 2022	-$2.81	-$3.48	-23.94%(-$0.67)
Q2 2022	Aug 31, 2022	-$2.76	-$3.74	-35.14%(-$0.97)

BNR Analyst Recommendations

Oct 2023

Nov 2023

Dec 2023

Jan 2024

4.00

Industry Peers — Health Services(30)

Symbol	Value Score	Growth Score	Momentum Score	P/E Ratio (Annual)	Revenue Growth TTM (YoY)	Operating Margin (TTM)	ROE (TTM)	Price
BNRBurning Rock Biotech Limited American Depositary Shares	C	F	B	—	-6.7%	-13.0%	-13.0%	$12.90
NTRANatera, Inc. Common Stock	F	A	A	—	37.8%	-10.7%	-11.7%	$393.44
DGXQuest Diagnostics Inc.	C	D	B	26.1x	9.9%	14.1%	14.5%	$235.00
LHLabcorp Holdings Inc.	C	D	B	29.4x	6.4%	10.4%	11.6%	$317.95
GHGuardant Health, Inc. Common Stock	F	A	B	—	42.7%	-40.2%	-246.6%	$158.60
CAICaris Life Sciences, Inc. Common Stock	F	A	B	—	38.5%	12.7%	18.8%	$30.56
RDNTRadNet, Inc. Common Stock	D	C	C	1779.3x	18.9%	3.0%	-1.9%	$68.80
GRALGRAIL, Inc. Common Stock	D	B	B	—	23.1%	-338.4%	-15.9%	$117.81
BLLNBillionToOne, Inc. Class A Common Stock	F	F	C	621.1x	—	10.9%	8.9%	$98.12
VCYTVeracyte, Inc.	D	B	C	52.2x	17.3%	19.6%	8.6%	$43.12
CDNACareDx, Inc.	D	B	A	18.3x	34.4%	23.6%	32.8%	$64.00
CELCCelcuity Inc. Common Stock	—	—	D	—	—	—	-244.6%	$56.58
FTREFortrea Holdings Inc. Common Stock	C	F	A	—	-2.1%	-0.4%	-15.5%	$22.49
PSNLPersonalis, Inc. Common Stock	F	D	B	—	-13.3%	-164.1%	-46.5%	$15.65
FRNMFreenome, Inc. Common stock	—	F	F	1507.5x	—	—	-0.9%	$11.75
LMRILumexa Imaging Holdings, Inc. Common Stock	C	C	C	—	—	8.2%	-8.7%	$10.78
CSTLCastle Biosciences, Inc. Common Stock	D	B	B	47.3x	3.2%	-9.0%	-4.2%	$31.96
FLGTFulgent Genetics, Inc. Common Stock	C	D	C	—	6.8%	-37.8%	-7.9%	$19.81
YDESYD Bio Limited Ordinary Shares	—	—	C	—	—	—	149.8%	$5.92
BDSXBiodesix, Inc. Common Stock	D	B	B	—	34.5%	-20.0%	-164.9%	$23.66
XGNExagen Inc. Common Stock	D	C	B	—	20.8%	-18.6%	-121.6%	$7.72
PCSCPerceptive Capital Solutions Corp Class A Ordinary Shares	—	F	C	147.2x	—	—	0.1%	$12.19
SERASera Prognostics, Inc. Class A Common Stock	D	C	C	—	-35.2%	-53282.9%	-46.7%	$2.06
MDXHMDxHealth SA Ordinary Shares	C	D	F	—	-5.2%	-16.6%	-305.0%	$0.21
AMSAmerican Shared Hospital Services	A	C	C	4.1x	4.0%	-11.8%	-7.5%	$1.28
ADVBAdvanced Biomed Inc. Common Stock	A	—	D	—	—	—	83.9%	$3.98
ACONAclarion, Inc. Common Stock	—	B	F	—	33.1%	-11592.2%	-59.3%	$1.85
BGLCBioNexus Gene Lab Corp Common stock	B	F	F	—	-67.1%	-81.8%	-32.9%	$1.20
ACONWAclarion, Inc. Warrant	—	—	D	—	—	—	—	$0.03
EXASExact Sciences Corp	F	B	B	—	17.7%	-6.3%	-8.5%	$0.00
YDESWYD Bio Limited Warrants	—	—	B	—	—	—	—	$0.60

About Burning Rock Biotech Limited American Depositary Shares

Burning Rock Biotech develops NGS-based cancer diagnostics platforms that help oncologists select optimal therapies for patients. The company operates through two revenue-generating channels: a central laboratory model serving smaller hospitals and an in-hospital model for larger medical centers, with the central laboratory business generating the majority of revenues. Its product portfolio includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, supplemented by pharma research and development services.